Evidence map›Paper›PMID 36076005›Full record

ArticleMolecular neurobiology2022

Specific Mutations in the Cholesterol-Binding Site of APP Alter Its Processing and Favor the Production of Shorter, Less Toxic Aβ Peptides.

Linda Hanbouch, Béatrice Schaack, Amal Kasri, Gaëlle Fontaine, Eleni Gkanatsiou, Gunnar Brinkmalm, Elena Camporesi, Erik Portelius, Kaj Blennow, Gilles Mourier and 6 more

Open access · hybridAbstract read
In one paragraph

Article in Molecular neurobiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Towards a Unitary Hypothesis of Alzheimer's Disease Pathogenesis.Journal of Alzheimer's disease : JAD · 2024
    Article
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 3 countries.

Linda Hanbouch *Paris Brain Institute, ICM, CNRS UMR7225-INSERM U1127-Sorbonne University Hôpital de La Pitié-Salpêtrière, 47 Bd de l'Hôpital, 75013, Paris, France.
Béatrice Schaack *Univ. Grenoble Alpes, CNRS, INP, TheRex Team, TIMC-IMAG, 38700, La Tronche, France.
Amal Kasri *Paris Brain Institute, ICM, CNRS UMR7225-INSERM U1127-Sorbonne University Hôpital de La Pitié-Salpêtrière, 47 Bd de l'Hôpital, 75013, Paris, France.
Gaëlle Fontaine *Paris Brain Institute, ICM, CNRS UMR7225-INSERM U1127-Sorbonne University Hôpital de La Pitié-Salpêtrière, 47 Bd de l'Hôpital, 75013, Paris, France.
Eleni GkanatsiouDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, S-431 80, Sweden.
Gunnar BrinkmalmDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, S-431 80, Sweden.
Elena CamporesiDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, S-431 80, Sweden.
Erik PorteliusDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, S-431 80, Sweden.
Kaj BlennowDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, S-431 80, Sweden.
Gilles MourierClinical Neurochemistry Laboratory, Sahlgrenska University Hospital, S-431 80, Mölndal, Sweden.
Nicolas GillesClinical Neurochemistry Laboratory, Sahlgrenska University Hospital, S-431 80, Mölndal, Sweden.
Mark J MillanNeuroscience Inflammation Thérapeutic Area, IDR Servier, 125 Chemin de Ronde, 78290, Croissy-sur-Seine, France.
Catherine MarquerParis Brain Institute, ICM, CNRS UMR7225-INSERM U1127-Sorbonne University Hôpital de La Pitié-Salpêtrière, 47 Bd de l'Hôpital, 75013, Paris, France.
Henrik ZetterbergDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, S-431 80, Sweden.
Lydie Boussicault *Paris Brain Institute, ICM, CNRS UMR7225-INSERM U1127-Sorbonne University Hôpital de La Pitié-Salpêtrière, 47 Bd de l'Hôpital, 75013, Paris, France.
Marie-Claude Potier *Paris Brain Institute, ICM, CNRS UMR7225-INSERM U1127-Sorbonne University Hôpital de La Pitié-Salpêtrière, 47 Bd de l'Hôpital, 75013, Paris, France. marie-claude.potier@upmc.fr.ORCID http://orcid.org/0000-0003-2462-7150
Centre National de la Recherche Scientifique · FRSahlgrenska University Hospital · SEUniversity of Gothenburg · SECommissariat à l'Énergie Atomique et aux Énergies Alternatives · FRServier (France) · FR

Funding

The effects of iron on oxidative stress and Alzheimer's biomarkers in amyloid-positive and negative elderly normalR01AG068398 · NIA · WEILL MEDICAL COLL OF CORNELL UNIV · PI CHIANG, GLORIA CHIA-YI · 2020 to 2024
$2.8M
Alzheimer's Association 2021 Zenith AwardEuropean Research Council #681712Medical Research Council MR/S005145/1NIA NIH HHS R01 AG068398NINR NIH HHS #1R01AG068398-01
6 · The paper itself

Abstract

Excess brain cholesterol is strongly implicated in the pathogenesis of Alzheimer's disease (AD). Here we evaluated how the presence of a cholesterol-binding site (CBS) in the transmembrane and juxtamembrane regions of the amyloid precursor protein (APP) regulates its processing. We generated nine point mutations in the APP gene, changing the charge and/or hydrophobicity of the amino-acids which were previously shown as part of the CBS. Most mutations triggered a reduction of amyloid-β peptides Aβ40 and Aβ42 secretion from transiently transfected HEK293T cells. Only the mutations at position 28 of Aβ in the APP sequence resulted in a concomitant significant increase in the production of shorter Aβ peptides. Mass spectrometry (MS) confirmed the predominance of Aβx-33 and Aβx-34 with the APP

Indexed as

Alzheimer DiseaseAmyloid beta-Protein PrecursorAmino AcidsAmyloid beta-PeptidesAmyloid Precursor Protein SecretasesBinding SitesCholesterolHEK293 CellsHumansMutationAmino AcidsAmyloid beta-PeptidesAmyloid beta-Protein PrecursorAmyloid Precursor Protein SecretasesCholesterolAlzheimer’s diseaseAmyloid precursor proteinAβCholesterolMutant

Identifiers

PMID36076005
PMCPMC9525381
OpenAlexW4295080275

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.